Faster-acting insulin aspart vs insulin aspart as part of basal–bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial
Saravanan, P. Bowering, K. Case, C. Harvey, J. Reeves, M. Sampson, M. Strzinek, R. Bretler, D. M. Bang, R. B. Bode, B. W.
Saravanan, P.
Bowering, K.
Case, C.
Harvey, J.
Reeves, M.
Sampson, M.
Strzinek, R.
Bretler, D. M.
Bang, R. B.
Bode, B. W.
Abstract
Poster abstract A46 (P110) in the section Science in clinical practice 1 from the Diabetes UK Professional Conference 2017, Manchester Central, Manchester, 8–10 March 2017.
MIDER Authors
Affiliations
University of Warwick; George Eliot Hospital, Nuneaton; University of Alberta, Canada; Jefferson City Medical Group, Missouri, USA; Bangor University, UK; Diabetes Clinical Trials, Chattanooga, Tennessee, USA; Norfolk and Norwich University Hospitals NHS Foundation Trust; Protenium Clinical Research, Hurst, Texas, USA; Novo Nordisk A/S, Søborg, Denmark; Atlanta Diabetes Associates, Georgia, USA
Citations
Altmetric:
Date
2017-03-08
Type
Conference Output
Subject
Citation
Saravanan P, Bowering K, Case C, Harvey J, Reeves M, Sampson M, Strzinek R, Bretler DM, Bang RB, Bode BW. Faster-acting insulin aspart vs insulin aspart as part of basal–bolus therapy improves postprandial glycaemic control in uncontrolled Type 2 diabetes in the double-blinded onset 2 trial. Diabetic Medicine. 2017 Mar;34(S1):21. doi: 10.1111/dme.8_13303.